Mingyao Li, PhD, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania.
Peter Mueller, PhD, Department of Mathematics, Department of Statistics and Data Sciences, University of Texas at Austin
Lu Mao, PhD, Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison
Snehalata Huzurbazar, PhD, Department of Biostatistics, West Virginia University
Meetings of the Eastern North American Region of the International Biometric Society (a.k.a. "ENAR meetings") are held in late March or early April each year and reflect the broad interests of the Society, including both quantitative techniques and application areas. Faculty and student presenters from the Department of Biostatistics regularly participate giving invited talks, contributed talks, and poster presentations.
The Joint Statistical Meetings, known simply as "JSM", is the largest gathering of statisticians held annually in North American. Faculty and student presenters from the Department of Biostatistics regularly participate giving invited talks, contributed talks, and poster presentations. Our students often receive top awards and participate in the affiliated career marketplace at the event.
Biostatistics Seminar guest speaker, Ying Huang, Fred Hutchinson Cancer Research Center, will present, "Inferential Procedures for the Use of Biomarkers in Treatment Selection".
Biomarkers associated with treatment-effect heterogeneity have the potential to make treatment recommendations more personalized to achieve the best clinical outcomes. While interest in the development of statistical methodology for estimating optimal treatment-selection biomarker panels has grown in recent years, the corresponding developments in inference have been inadequate. In this talk we will present two recent developments on inferential procedures for the use of biomarkers in treatment selection, motivated by data arising from HIV-1 vaccine trials. The first problem focuses on the personalized use of a treatment-selection biomarker panel developed using either a risk modeling approach or a policy-based approach. We propose inferential procedures on a new biomarker-panel’s covariate-specific incremental value, for the purpose of identifying subpopulations that will benefit most from the marker panel. The second problem focuses on the use of threshold regression models to identify subgroups with heterogeneous treatment effect. We propose procedures for testing the existence of biomarker combinations that naturally separate a population into such subgroups.
Last Updated On Thursday, October 12, 2017 by Haydo, Amber LC
Created On Wednesday, August 09, 2017